Investors Lose Money on Pacira BioSciences, Join Class Action Now
Pacira BioSciences, Inc. Faces Class Action Lawsuit
Investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) are facing challenging times as news arises about a significant class action securities lawsuit. This alert comes as an important notice for shareholders who may have experienced financial losses relating to their investments in the company.
Details of the Class Action Lawsuit
The class action lawsuit aims to seek recovery of losses incurred by investors adversely affected by alleged securities fraud that occurred in a specified period. This situation is particularly concerning for those who invested in Pacira between certain dates, as many may not be aware of their rights to pursue legal action.
Understanding the Impact of the Lawsuit
On examining the complaint, it was highlighted that Pacira issued a press release about the results of its recent patent infringement lawsuit, which raises several red flags. The court found that the company's critical patent, U.S. Patent No. 11,033,495, was deemed invalid. This revelation is significant as it directly impacts Exparel, which constitutes approximately 80% of Pacira's revenue.
Market Reaction to Patent Invalidation
Following the announcement, the company’s stock experienced a drastic decline. Investors saw the price plummet from $22.36 per share to a shocking low of $11.70, marking a more than 47% decrease in just one day. As a result, numerous shareholders are now reevaluating their positions and considering joining the class action to recover their losses.
What's Next for Affected Investors?
For those who believe they have suffered losses during the relevant timeframe, there is a clear path forward. Interested parties have a deadline to request to be appointed as lead plaintiffs in the case, which provides an opportunity for individual investors to assert their claims.
Cost-Free Participation
One crucial aspect for investors to note is that joining this class action carries no cost. Investors can participate without incurring any out-of-pocket expenses or fees, making it a viable option for those looking to recover losses without financial risk.
Expertise of Levi & Korsinsky
Levi & Korsinsky, LLP is spearheading this class action and boasts a strong track record of representing investors in complex securities litigation. With more than 20 years of experience, they have recovered substantial amounts for aggrieved shareholders and have a dedicated team to ensure robust representation.
Contact Information for Investors
Shareholders who are interested in learning more or who wish to participate in the class action may reach out to Levi & Korsinsky directly. Joseph E. Levi, Esq. is available to assist and provide further information on how to proceed with your claim. Investors can expect professional guidance throughout the process.
Frequently Asked Questions
What is the purpose of the class action lawsuit?
The lawsuit aims to recover losses for investors in Pacira BioSciences, Inc. who have been adversely affected by alleged securities fraud.
How can I participate in the class action?
If you have suffered losses, you can express your interest and potentially be appointed as a lead plaintiff by contacting Levi & Korsinsky before the deadline.
Is there any cost to join the class action?
No, participating in the class action is free of charge, and you will not incur any expenses.
What happened to Pacira's stock value recently?
Pacira’s stock value dropped significantly after the court ruled the company's major patent invalid, causing investors considerable financial losses.
Who can I contact for more information?
You can reach out to Joseph E. Levi, Esq. at Levi & Korsinsky for further assistance and guidance regarding the class action.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
